AB Science S.A.

Paris Stock Exchange AB.PA

AB Science S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD 17.96 M

AB Science S.A. Net Cash Used Provided By Financing Activities is USD 17.96 M for the year ending December 31, 2023, a 2.42% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

AB Science S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD 17.54 M, a 163.62% change year over year.
AB Science S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 6.65 M, a -81.05% change year over year.
AB Science S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 35.10 M, a 221.32% change year over year.
AB Science S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 10.92 M, a 15,547.15% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

Paris Stock Exchange: AB.PA

AB Science S.A.

CEO	Mr. Alain Moussy MBA
IPO Date	April 26, 2010
Location	France
Headquarters	3, Avenue George V
Employees	40
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Vaccines

Description

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.

Key trends

Past 5 years